Hongbo Lu is Director at Terns Pharmaceuticals, Inc. (TERN). They have made 11 open-market trades across 4 companies since 2019, most recently 2026-05-12.
CIK 0001767584
11 open-market purchases totalling $32.3M since 2019, never a sale. Across 11 scored buys the stock is down 5.9% at ninety days, and 10.9 points behind the S&P over the same stretch.
11 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| TPTX | 1,120,730 | $85.2M |
| ZBIO | 426,736 | $10.6M |
| TERN | 190,476 | $10.1M |
| ARWR | 52,012 | $2.9M |
| Total | $108.8M |
Shares reported on the most recent Form 4, priced at the 2026-05-14 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 36% | 45% | 45% |
| Avg Move | -0.2% | +4.2% | -5.9% |
| Alpha | +0.3% | +4.0% | -10.9% |
| Scored | 11 | 11 | 11 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ARWR | SELL · 10b5-1 | 2026-05-12 | 2026-05-14 | $76.88 | $228K | +1.2% | -1.0% | +11.9% |
| ZBIO | BUY | 2026-03-31 | 2026-04-02 | $18.63 | $70K | -2.2% | +0.0% | +30.4% |
| ZBIO | BUY | 2026-03-31 | 2026-03-31 | $20.00 | $1.5M | +3.3% | -5.0% | +25.3% |
| ZBIO | BUY | 2026-02-11 | 2026-02-13 | $22.50 | $585K | -9.6% | -20.4% | -35.2% |
| ZBIO | BUY | 2025-10-07 | 2025-10-09 | $19.00 | $5.0M | -11.1% | +10.9% | -43.6% |
| ZBIO | BUY | 2024-09-13 | 2024-09-17 | $17.00 | $1000K | -4.7% | +19.3% | -51.3% |
| TERN | BUY | 2024-09-12 | 2024-09-17 | $10.50 | $5.0M | -14.4% | -24.9% | -30.1% |
| ARWR | BUY | 2024-03-18 | 2024-03-20 | $27.66 | $83K | -9.6% | -22.9% | -18.6% |
| TERN | BUY | 2022-12-23 | 2022-12-23 | $7.25 | $5.5M | +7.9% | -2.1% | +7.6% |
| TERN | BUY | 2022-09-07 | 2022-09-08 | $3.60 | $2.2M | +29.2% | +18.6% | +19.9% |
| TERN | BUY | 2022-08-12 | 2022-08-16 | $2.76 | $10.3M | -10.2% | +27.9% | -8.0% |
| TPTX | BUY | 2019-04-22 | 2019-04-24 | $18.00 | $1.1M | +19.8% | +45.3% | +38.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.